564 related articles for article (PubMed ID: 28826027)
1. CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons.
Qing X; Walter J; Jarazo J; Arias-Fuenzalida J; Hillje AL; Schwamborn JC
Stem Cell Res; 2017 Oct; 24():44-50. PubMed ID: 28826027
[TBL] [Abstract][Full Text] [Related]
2. In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson's Disease in Common Marmosets.
Vermilyea SC; Babinski A; Tran N; To S; Guthrie S; Kluss JH; Schmidt JK; Wiepz GJ; Meyer MG; Murphy ME; Cookson MR; Emborg ME; Golos TG
Sci Rep; 2020 Feb; 10(1):3447. PubMed ID: 32103062
[TBL] [Abstract][Full Text] [Related]
3. In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation.
Chang KH; Huang CY; Ou-Yang CH; Ho CH; Lin HY; Hsu CL; Chen YT; Chou YC; Chen YJ; Chen Y; Lin JL; Wang JK; Lin PW; Lin YR; Lin MH; Tseng CK; Lin CH
Stem Cell Res Ther; 2021 Sep; 12(1):508. PubMed ID: 34551822
[TBL] [Abstract][Full Text] [Related]
4. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
Ho DH; Seol W; Son I
Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
[TBL] [Abstract][Full Text] [Related]
6. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase.
Ho DH; Kim H; Nam D; Sim H; Kim J; Kim HG; Son I; Seol W
Cell Biochem Funct; 2018 Dec; 36(8):431-442. PubMed ID: 30411383
[TBL] [Abstract][Full Text] [Related]
8. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.
Schwab AJ; Sison SL; Meade MR; Broniowska KA; Corbett JA; Ebert AD
Stem Cell Reports; 2017 Dec; 9(6):1839-1852. PubMed ID: 29129681
[TBL] [Abstract][Full Text] [Related]
9. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.
Novello S; Arcuri L; Dovero S; Dutheil N; Shimshek DR; Bezard E; Morari M
Neurobiol Dis; 2018 Dec; 120():21-33. PubMed ID: 30172844
[TBL] [Abstract][Full Text] [Related]
10. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
[TBL] [Abstract][Full Text] [Related]
12. The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.
Cresto N; Gardier C; Gaillard MC; Gubinelli F; Roost P; Molina D; Josephine C; Dufour N; Auregan G; Guillermier M; Bernier S; Jan C; Gipchtein P; Hantraye P; Chartier-Harlin MC; Bonvento G; Van Camp N; Taymans JM; Cambon K; Liot G; Bemelmans AP; Brouillet E
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201785
[TBL] [Abstract][Full Text] [Related]
13. Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice.
Xiong Y; Neifert S; Karuppagounder SS; Liu Q; Stankowski JN; Lee BD; Ko HS; Lee Y; Grima JC; Mao X; Jiang H; Kang SU; Swing DA; Iacovitti L; Tessarollo L; Dawson TM; Dawson VL
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1635-1640. PubMed ID: 29386392
[TBL] [Abstract][Full Text] [Related]
14. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
[TBL] [Abstract][Full Text] [Related]
15. Modeling Parkinson's disease using induced pluripotent stem cells.
Byers B; Lee HL; Reijo Pera R
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects.
Borgs L; Peyre E; Alix P; Hanon K; Grobarczyk B; Godin JD; Purnelle A; Krusy N; Maquet P; Lefebvre P; Seutin V; Malgrange B; Nguyen L
Sci Rep; 2016 Sep; 6():33377. PubMed ID: 27640816
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
eNeuro; 2017; 4(2):. PubMed ID: 28321439
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
Henderson MX; Peng C; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
